{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:08:51Z","timestamp":1791562131374,"version":"4.3.4"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"19","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> As glioblastoma progresses, patients experience a decline in health-related quality of life (HRQoL). Delaying this decline is an important treatment goal. In newly diagnosed glioblastoma, progression-free survival was prolonged when bevacizumab was added to radiotherapy plus temozolomide (RT\/TMZ) versus placebo plus RT\/TMZ (phase III AVAglio study; hazard ratio, 0.64; 95% CI, 0.55 to 0.74; P &lt; .001). To ensure that addition of bevacizumab to standard-of-care therapy was not associated with HRQoL detriment, HRQoL assessment was a secondary objective. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients completed European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires C30 and BN20 at each tumor assessment (Appendix Table A1 , online only). Raw scores were converted to a 100-point scale and mean changes from baseline scores were evaluated (stable: &lt; 10-point change; clinically relevant deterioration\/improvement: \u2265 10-point change). Deterioration-free survival was the time to deterioration\/progression\/death; time to deterioration was the time to deterioration\/death. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Most evaluable patients who had not progressed (&gt; 74%) completed all HRQoL assessments for at least 1 year of treatment, and almost all completed at least one HRQoL assessment at baseline (98.3% and 97.6%, bevacizumab and placebo arms, respectively). Mean changes from baseline did not reach a clinically relevant difference between arms for most items. HRQoL declined at progression in both arms. The addition of bevacizumab to RT\/TMZ resulted in statistically longer (P &lt; .001) deterioration-free survival across all items. Time to deterioration was not statistically longer in the placebo plus RT\/TMZ arm (v bevacizumab) for any HRQoL item. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The addition of bevacizumab to standard-of-care treatment for newly diagnosed glioblastoma had no impact on HRQoL during the progression-free period. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2014.60.3217","type":"journal-article","created":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T14:36:58Z","timestamp":1432737418000},"page":"2166-2175","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":117,"title":["Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma"],"prefix":"10.1200","volume":"33","author":[{"given":"Martin J.B.","family":"Taphoorn","sequence":"first","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Henriksson","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bottomley","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren P.","family":"Mason","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Saran","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Hilton","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Theodore-Oklota","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arliene","family":"Ravelo","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier L.","family":"Chinot","sequence":"additional","affiliation":[{"name":"Martin J.B. Taphoorn, Medical Center Haaglanden, the Hague, and VU University Medical Center, Amsterdam, the Netherlands; Roger Henriksson, Cancer Center Stockholm Gotland, Karolinska, Stockholm, and Ume\u00e5 University, Ume\u00e5, Sweden; Andrew Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Timothy Cloughesy, University of California, Los Angeles, Los Angeles; Christina Theodore-Oklota and Arliene Ravelo, Genentech, South San Francisco, CA; Wolfgang Wick, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903052764"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-492-0_14"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0565-x"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005790632126"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00680-5"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0291"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-9923-3"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1586\/erp.12.70"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-012-0813-8"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1994.80.2.0247"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-9946-9"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)02645-1"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.17.1485"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.128"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11398-5"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055862.20003.4A"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.5605"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00165-9"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.3183"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/2.4.221"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.01.012"},{"key":"B27","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers P","year":"2001"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1316"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1340-4"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70432-0"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.2003"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023900802254"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065901"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2014.60.3217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:49:35Z","timestamp":1653522575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2014.60.3217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,1]]},"references-count":33,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2015,7,1]]}},"alternative-id":["10.1200\/JCO.2014.60.3217"],"URL":"https:\/\/doi.org\/10.1200\/jco.2014.60.3217","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,1]]},"assertion":[{"value":"2015-05-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}